Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. Its lead candidate, Lanifibranor, a novel pan-peroxisome proliferator-activated receptor (PPAR) agonist, is in the Phase 3 NATiV3 clinical trial for treating metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), targeting key disease features like steatosis, inflammation, ballooning, and fibrosis. The company also advances Odiparcil for mucopolysaccharidoses (MPS), rare genetic disorders involving glycosaminoglycan accumulation, and earlier-stage programs including TGF-β for idiopathic pulmonary fibrosis and initiatives in oncology. Founded in 2011 and headquartered in Daix, France, Inventiva leverages a proprietary library of 240,000 compounds, a dedicated R&D facility, and expertise in nuclear receptors and epigenetic modulation. With around 118 employees, including co-founders CEO Frederic Cren and CSO Pierre Broqua, it maintains partnerships like those with Sino Biopharm and Hepalys Pharma, underscoring its role in advancing innovative treatments within the biotechnology sector of healthcare.